RCUS

Arcus Biosciences
RCUS

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.12B
EV
$326.91M
Shares Outstanding
106.43M
Beta
0.89

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$28.36
P/E 2025E
-
P/Revenue 2025E
4.91x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Arcus Biosciences, Inc.

gainify
RCUS

Arcus Biosciences, Inc.

RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB...

Sector

Healthcare

Industry

Biotechnology

CEO

Rosen, Terry

Employees

627

IPO Date

2018-03-15

Headquarters

3928 Point Eden Way, Hayward, California, 94545, United States

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.